Explore citation-grounded hypotheses, methods, and pathways built from the literature, ready for your next experiment. Each brief opens as a live BioSkepsis research conversation you can continue inside the app.
Curated insights into disease-relevant molecular pathways and gene networks. Each brief is backed by a live BioSkepsis research conversation. Open it in the app to trace mechanisms, branch into specific targets, or compare pathways across conditions.
How 15-PGDH accumulation drains PGE2 from aging cartilage, drives chondrocyte hypertrophy, and how its inhibition restores hyaline cartilage synthesis.
Jun 12, 2026
Microplastics reduce fecal pellet sinking by 34%, alias radiocarbon dating by 4,000 years, and replace biogenic carbon with synthetic polymer at ocean depth.
Jun 5, 2026
Oleic acid drives PDAC stemness and ferroptosis resistance via SCD1. Linoleic acid induces ferroptosis through lipid peroxidation and RIP3/MLKL necroptosis.
Jun 5, 2026
NFIL3 converts chronic IL-2 signaling into T-cell exhaustion by recruiting G9a, SUV39H1, and EZH2 to silence effector genes and drive TIM-3 in CAR-T cells.
Jun 5, 2026
Ultra-processed food additives drive gut dysbiosis via TLR4/NF-kB activation and mucus barrier disruption, fueling CRP/IL-6 metaflammation and chronic disease.
May 24, 2026
In vivo Cas9/LNP editing of KLKB1 in hepatocytes permanently silences plasma kallikrein production, eliminating bradykinin-mediated angioedema attacks in HAE.
May 24, 2026
Cas9 editing at HBB triggers MMEJ-driven kilobase deletions, micronuclei-mediated chromosomal loss, and LOA disrupting fetal hemoglobin compensation.
May 24, 2026
mRNA neoantigen vaccines use LNP delivery to encode tumor-specific mutations, engage MHC-I/II antigen presentation, and activate CD8+ and CD4+ T-cell responses.
May 23, 2026
How on-target mutations, bypass signaling via MET and ERBB3, lineage plasticity, and APOBEC3B-driven mutagenesis interact to drive inevitable resistance in KRAS- and EGFR-mutant lung cancer.
May 20, 2026
Molecular signaling networks driving MASLD steatosis through MASH fibrosis to hepatocellular carcinoma, and how converging lipotoxic, fibrogenic, and immune axes create the immunologically cold MASH-HCC TME.
May 20, 2026
Can't find the molecular pathway or research frontier you want? Submit a request and suggest how we can expand our library of peer-reviewed insights and mechanistic hypotheses with evidence-grounded hypotheses.